Business Description
Erasca Inc
NAICS : 541714
SIC : 2834
ISIN : US29479A1088
Total Employee Number:
103Description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.01 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.3 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.2 | |||||
3-Year EPS without NRI Growth Rate | 29.4 | |||||
3-Year FCF Growth Rate | 27.7 | |||||
3-Year Book Growth Rate | -25.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.2 | |||||
9-Day RSI | 43.63 | |||||
14-Day RSI | 46.89 | |||||
3-1 Month Momentum % | 67 | |||||
6-1 Month Momentum % | 54.55 | |||||
12-1 Month Momentum % | 1192 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.29 | |||||
Quick Ratio | 8.29 | |||||
Cash Ratio | 8.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.9 | |||||
Shareholder Yield % | -4.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -79.75 | |||||
ROA % | -66.54 | |||||
ROIC % | -94.55 | |||||
3-Year ROIIC % | 31.74 | |||||
ROC (Joel Greenblatt) % | -354.78 | |||||
ROCE % | -37.43 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 15.24 | |||||
Price-to-Tangible-Book | 15.22 | |||||
EV-to-EBIT | -39.48 | |||||
EV-to-Forward-EBIT | -17.43 | |||||
EV-to-EBITDA | -40.27 | |||||
EV-to-Forward-Revenue | 22.65 | |||||
EV-to-FCF | -23.6 | |||||
| Price-to-Net-Current-Asset-Value | 26.74 | |||||
| Price-to-Net-Cash | 28.02 | |||||
Earnings Yield (Greenblatt) % | -2.53 | |||||
FCF Yield % | -4.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ERAS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Erasca Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.95 | ||
| Beta | -0.4983 | ||
| 3-Year Sharpe Ratio | 0.89 | ||
| 3-Year Sortino Ratio | 2.72 | ||
| Volatility % | 179.94 | ||
| 14-Day RSI | 46.89 | ||
| 14-Day ATR ($) | 1.052693 | ||
| 20-Day SMA ($) | 18.1765 | ||
| 12-1 Month Momentum % | 1192 | ||
| 52-Week Range ($) | 1.3301 - 24.28 | ||
| Shares Outstanding (Mil) | 349.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Erasca Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Erasca Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 80 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 18.12 (-0.17%) | ||
| General meeting for 2026 | 2026-06-26 11:30 | 14.95 (-0.86%) | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-03 15:10 | 13.48 (-2.32%) | ||
| Guidance call for 2026 | 2026-05-13 15:00 | 10.38 (+1.57%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 10.12 (-3.34%) | ||
| ERAS-0015 Phase 1 Data Call | 2026-04-27 16:30 | 21.49 (-4.32%) | ||
| Annual report for 2025 | 2026-03-12 | 15.50 (+0.65%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 15.50 (+0.65%) | ||
| Oppenheimer 36(th) Annual Healthcare Life Sciences Conference | 2026-02-26 11:20 | 13.46 (-1.26%) |
Show
Entries
Erasca Inc Frequently Asked Questions
What is Erasca Inc(ERAS)'s stock price today?
The current price of ERAS is $17.65. The 52 week high of ERAS is $24.28 and 52 week low is $1.33.
When is next earnings date of Erasca Inc(ERAS)?
The next earnings date of Erasca Inc(ERAS) is 2026-11-12 Est..
Does Erasca Inc(ERAS) pay dividends? If so, how much?
Erasca Inc(ERAS) does not pay dividend.
Press Release
Articles on Erasca Inc
ERAS SWOT Analysis: Financial Challenges and Strategic Opportunities Revealed in 10-Q Filing
Aug 12, 2026
Erasca Inc (ERAS) Advances RAS-Targeted Cancer Therapies Amid High Valuation and Mixed Financial Signals
Aug 11, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers